Anki Malmborg Hager
Chief Executive Officer since 2014
Anki Malmborg Hager has a PhD in Immunotechnology and MSc in chemical engineering from the Faculty of Engineering at Lund University. Anki Malmborg Hager has also studied for an MBA with special focus on the pharmaceutical industry as well as executive training at Executive Foundation Lund.
Current appointments: Anki Malmborg Hager is a member of the Board of Avena Partners AB, DiaProst AB, Hager Consulting AB and Immunovia AB.
Previous appointments (last five years): Board member of Bulb Intelligence AB, Cantargia AB and WC Likvid AB. Managing Director of Sista versen 26366 AB.
Mikael Wahlgren
Deputy Chief Executive Officer since 2018
Mikael Wahlgren has a LLM in Law from the Faculty of Law at Lund University. Mikael Wahlgren has also studied to become a Barrister at the Honourable Society of the Inner Temple in London (being a Barrister not active), the Chairman of the Board training at Swedish Board Academy, the Board Programme at Executive Foundation Lund (being a Certified Board Member) and Mediator skill training at the Centre for Efficient Dispute Resolution (being a CEDR accredited mediator). Mikael has previously worked as the Group General Counsel for Alfa Laval as well as an in-house Counsel for several multinational companies. Since 2016, he runs a legal consultancy business in which he acts as Senior Legal Adviser.
Current appointments: Member of the Board and Deputy Managing Director of Dignitana AB, owner and member of the Board of Linton & Wahlgren AB, Chairman of the Board of Gran Man AB and Chief Compliance Officer of FINQR AB.
Previous appointments (last five years): Chairman of the Board of Nattaro Labs AB and Arc Aroma Pure AB, Group General Counsel of Alfa Laval AB.
Maria Agemark
Chief Operating Officer since 2018
Maria Agemark holds a PhD in biochemistry and a Bachelor’s degree in molecular biology from Lund University. Prior to her current position, Maria Agemark was employed as Laboratory and Quality Manager and earlier as a research engineer at SenzaGen. Maria Agemark has previously worked as a postdoctoral researcher at the Department of Immunotechnology at Lund University.
Current appointments: Partner and board member of GFM
Förvaltning AB.
Previous appointments (last five years): Alternate board member of ApoGlyx AB.
Marianne Olsson
Chief Financial Officer since 2016
Marianne Olsson is an economist, educated at Malmö Latin School and has previously worked as a department economist, economist and most recently as administrative manager at the Department of Immunotechnology at Lund University. Marianne Olsson has studied courses in accounting at Lund University and has conducted several internal and external leadership-related courses.
In addition, Marianne Olsson has been a member of the Board of the Faculty of Engineering at Lund University, as well as a member of the management and Department board at the Department of Immunotechnology.
Current appointments: None.
Previous appointments (last five years): None.
Stephen Smith
Intellectual Property counsel since 2017
Stephen holds a PhD in Neuroscience and a Master’s degree in Biochemistry from the University of Oxford in the UK. He is an experienced European patent attorney and Chartered (UK) patent attorney, who specialises in biotechnology inventions, with particular expertise in therapeutic/diagnostic antibodies and disease biomarkers. He joined the intellectual property law firm Potter Clarkson in 1998, becoming a partner in 2007 and joining the Board of Management in 2013. Stephen acts for a range of clients including multinational companies, early-stage and established biotech companies based throughout Europe, as well as government-funded research institutes and universities.
Current appointments: Partner and member of the Board of Management at Potter Clarkson LLP.
Previous appointments (last five years): None.
Anna Chérouvrier Hansson
Chief Commercial Officer since 2017
Anna has extensive experience from marketing, sales and business development positions in the life science industry. She has previously worked with commercialization of products at a number of companies including Camurus, Novo Nordisk, Gambro and DuPont with positions in Sweden, Denmark, Luxembourg and Germany. In addition, Anna has been one of four partners at Zitha Consulting, working on behalf of pharmaceutical companies and their commercialization strategies and head of life science inward investment activities at Invest in Skåne. Anna holds a Master‘s degree in European Business Administration from Lund University and a Bachelor’s degree in Business Administration and Management from the European Partnership of Business Schools.
Current appointments: Board member MVIC (Medicon Valley Inhalation Consortium)Partner and board member Nordå Gård AB
Previous appointments (last five years): Director of Marketing at Camurus ABHead of Business Development Life Science at Invest in Skåne AB
Gunilla Grundström
Chief Scientific Officer since 2018
Gunilla Grundström has a PhD in Medical Biochemistry from the Medical Faculty at Uppsala University and a MSc in chemical engineering from the Faculty of Engineering at Lund University. Gunilla Grundström is an experienced research and people manager with 10+ years within Life Science and MedTech industry. Prior to her current position Gunilla Grundström held a position as Sr Research Manager at Baxter (Gambro) where she also has held positions as Principal and Sr Research Scientist. In addition, Gunilla Grundström has experience from the Pharma industry as postdoctoral researcher at AstraZeneca.
Current appointments: None
Previous appointments (last five years): Employee representative in the boards of Gambro AB and Gambro Lundia AB
